Format

Send to

Choose Destination
Anticancer Res. 2017 May;37(5):2709-2713.

Dose Escalation Improves Outcome in Stereotactic Body Radiotherapy for Pulmonary Oligometastases from Colorectal Cancer.

Author information

1
Department of Radiation Oncology, Graduate School of Medicine, Tohoku University Sendai, Japan kjingu-jr@rad.med.tohoku.ac.jp.
2
Department of Radiation Oncology and Image-applied Therapy, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
3
Department of Radiology, Graduate School of Medicine, Yamanashi University, Yamanashi, Japan.
4
Department of Radiation Oncology, Graduate School of Medicine, Tohoku University Sendai, Japan.
5
Department of Radiology and Radiation Oncology, Graduate School of Medicine, Hirosaki University, Hirosaki, Japan.
6
Department of Radiation Oncology, Graduate School of Medicine, Hiroshima University, Hiroshima, Japan.
7
Department of Radiology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
8
Department of Radiology, School of Medicine, Iwate Medical University, Morioka, Japan.
9
Department of Radiology, Graduate School of Medicine, Yamagata University, Yamagata, Japan.
10
Department of Radiation Oncology, Osaki Citizen Hospital, Furukawa, Japan.
11
Department of Radiation Oncology, Graduate School of Medicine, Gunma University, Maebashi, Japan.
12
Department of Radiology, Toho University Omori Medical Center, Tokyo, Japan.
13
Department of Radiation Oncology, Graduate School of Medicine, Osaka University, Osaka, Japan.

Abstract

AIM:

To evaluate the efficacy of stereotactic body radiotherapy (SBRT) for pulmonary metastasis from colorectal cancer.

PATIENTS AND METHODS:

Data for 104 lesions from 93 patients who underwent SBRT for pulmonary oligometastases from colorectal cancer at ten Institutions were retrospectively analyzed. Toxicity was graded according to the Common Terminology Criteria for Adverse Events v4.0.

RESULTS:

The median calculated biological effective dose using the linear-quadratic model with α/β of 10 Gy (BED10) was 105.6 Gy. Adjuvant chemotherapy after SBRT was performed in 47 patients. The median observation period was 28 months. The 3- and 5-year local control rates were 65.2% and 56.2%, respectively. The 3- and 5-year overall survival rates were 55.9% and 42.7%, respectively. Only two patients had grade 3 radiation pneumonitis. In multivariate analysis for local control, primary site, age, adjuvant chemotherapy after SBRT and BED10 were selected as prognostic factors.

CONCLUSION:

Dose escalation and adjuvant chemotherapy might improve local control in SBRT for pulmonary oligometastases from colorectal cancer.

KEYWORDS:

Oligometastases; SBRT; colorectal cancer; dose-escalation

PMID:
28476849
DOI:
10.21873/anticanres.11621
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center